|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0111429,
umls-concept:C0249197,
umls-concept:C0288472,
umls-concept:C0332325,
umls-concept:C0376315,
umls-concept:C0424295,
umls-concept:C0598086,
umls-concept:C0598388,
umls-concept:C1415887,
umls-concept:C1419040,
umls-concept:C1420433,
umls-concept:C1420626,
umls-concept:C1424666
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2005-4-11
|
|
pubmed:abstractText |
The low molecular weight (LMW) isoforms of cyclin E are unique to cancer cells. In breast cancer, such alteration of cyclin E is a very strong predictor of poor patient outcome. Here we show that alteration in binding properties of these LMW isoforms to CDK2 and the CDK inhibitors (CKIs), p21 and p27, results in their functional hyperactivity. The LMW forms of cyclin E are severalfold more effective at binding to CDK2. Additionally, compared with the full-length cyclin E-CDK2 complexes, the LMW cyclin E-CDK2 complexes are significantly more resistant to inhibition by p21 and p27, despite equal binding of the CKIs to the LMW complexes. When both the full-length and the LMW cyclin E are co-expressed, p27 preferentially binds to the LMW forms yet is unable to inhibit the CDK2 activity. Thus, the LMW forms of cyclin E may contribute to tumorigenesis through their resistance to the inhibitory activities of p21 and p27 while sequestering these CKIs from the full-length cyclin E.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CDC2-CDC28 Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/CDK2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Cycle Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin E,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Glutathione Transferase,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Isoforms,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0021-9258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
280
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
15148-57
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15708847-Animals,
pubmed-meshheading:15708847-Breast Neoplasms,
pubmed-meshheading:15708847-CDC2-CDC28 Kinases,
pubmed-meshheading:15708847-Cell Cycle Proteins,
pubmed-meshheading:15708847-Cell Line,
pubmed-meshheading:15708847-Cell Line, Tumor,
pubmed-meshheading:15708847-Cyclin E,
pubmed-meshheading:15708847-Cyclin-Dependent Kinase 2,
pubmed-meshheading:15708847-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:15708847-Cyclin-Dependent Kinase Inhibitor p27,
pubmed-meshheading:15708847-Dose-Response Relationship, Drug,
pubmed-meshheading:15708847-Glutathione Transferase,
pubmed-meshheading:15708847-Humans,
pubmed-meshheading:15708847-Immunoprecipitation,
pubmed-meshheading:15708847-Insects,
pubmed-meshheading:15708847-Plasmids,
pubmed-meshheading:15708847-Protein Binding,
pubmed-meshheading:15708847-Protein Isoforms,
pubmed-meshheading:15708847-Protein Structure, Tertiary,
pubmed-meshheading:15708847-Time Factors,
pubmed-meshheading:15708847-Tumor Suppressor Proteins
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
|
|
pubmed:affiliation |
Department of Experimental Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4095, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, N.I.H., Extramural
|
